An Open-label, Randomized, Crossover Study to Investigate the Comparative Pharmacodynamics and Pharmacodynamics Equivalence of Antareit 800 mg/10 ml Oral Suspension and Riopan 800 mg Chewable Tablets in Healthy Volunteers.

Status: Recruiting
Location: See all (2) locations...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

Comparative study of the pharmacodynamic parameters and pharmacodynamic equivalence (bioequivalence) of drug Antareit 800 mg/10 ml oral suspension and drug Riopan 800 mg chewable tablets in healthy volunteers.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 45
Healthy Volunteers: t
View:

• Voluntary and handwritten informed consent form signed by a healthy volunteer to participate in the study prior to any of the study procedures;

• Healthy male and female caucasian volunteers aged 18 to 45 years (inclusive);

• Verified diagnosis healthy (without abnormal findings in the protocol-defined clinical, laboratory, and instrumental test data);

• pH according to hourly pH-metry in the screening period, carried out at least 3 hours after the last meal, is completely in the range from 1 to 3 inclusive throughout the entire astronomical hour of measurement;

• Blood pressure (BP) levels: 100 to 139 mm Hg, inclusive (systolic, SBP), 60 to 89 mm Hg, inclusive (diastolic, DBP);

• Heart rate (HR) of 60 to 90 bpm, inclusive;

• Body mass index (BMI) of 18.5 kg/m2 ≤ BMI ≤ 30 kg/m2, where the body weight range is ≥ 55 kg for men and ≥ 45 kg for women;

• Non-smoking healthy volunteers (who have never smoked or gave up smoking more than 6 months prior to the Screening);

• Consent to use adequate methods of contraception throughout the study and for 30 days after completion; for women of preserved reproductive potential, a negative urine pregnancy test result;

⁃ The volunteers must have adequate behavior and coherent speech.

Locations
Other Locations
Russian Federation
Llc Certa Clinic
RECRUITING
Moscow
Limited Liability Company Research Center Eco-Safety
RECRUITING
Saint Petersburg
Time Frame
Start Date: 2024-04-25
Estimated Completion Date: 2025-09-20
Participants
Target number of participants: 50
Treatments
Experimental: TR-sequence (T-test drug, R-reference drug)
Group 1 (25 volunteers, TR sequence) will take 2 sachets of Antareit 800 mg/10 ml oral suspension 2 h prior to food intake in Period 1 and 2 tablets of Riopan 800 mg chewable tablets 2 h prior to food intake in Period 2
Experimental: RT-sequence
Group 2 (25 volunteers, RT sequence) will take 2 tablets of Riopan 800 mg chewable tablets 2 h prior to food intake in Period 1 and 2 sachets of Antareit 800 mg/10 ml oral suspension 2 h prior to food intake in Period 2
Related Therapeutic Areas
Sponsors
Leads: Valenta Pharm JSC

This content was sourced from clinicaltrials.gov